Low-dose CT screening for patients at high risk of lung cancer can find smaller nodules than X-ray, but concern remains about potential harm from the test.
Low-dose CT screening for patients who are at increased risk of developing lung cancer can identify smaller nodules than can chest X-rays. But concern remains regarding potential harm from the screening, according to a study published online in JAMA.
Peter B. Bach, MD, of the Memorial Sloan-Kettering Cancer Center, New York, and colleagues assessed the results of several randomized controlled trials and cohort studies, finding that the National Lung Screening trial was the most informative, with 53,545 participants. The findings showed that the screening resulted in a 20 percent lower relative risk of death.
“In terms of potential harms of [low-dose CT] screening, across all trials and cohorts, approximately 20 percent of individuals in each round of screening had positive results requiring some degree of follow-up, while approximately 1 percent had lung cancer,” the study authors wrote.
“There was marked heterogeneity in this finding and in the frequency of follow-up investigations, biopsies, and percentage of surgical procedures performed in patients with benign lesions.”
The study authors concluded, however, that there is still uncertainty about the potential harms of screening and generalizability of the results.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.